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Abstract
Background: Higher exposure to certain phthalates is associated with a diabetes and insulin resistance, with sex
differences seen. Yet, little is known about the association between phthalates and metabolic syndrome (MetS),
particularly with consideration for differences by sex and menopausal status.
Methods: We analyzed data from 2719 participants in the National Health and Nutrition Examination Survey
(NHANES) 2001–2010 aged 20–80 years. Five urinary phthalate metabolites (MEP, MnBP, MiBP, MBzP, and MCPP)
and DEHP metabolites were analyzed by the Centers for Disease Control and Prevention and were evaluated as
population-specific quartiles. MetS was defined by National Cholesterol Education Program’s Adult Treatment
Panel III report criteria. Prevalence odds ratios (POR) and 95 % confidence intervals (CI) were calculated using
multivariable logistic regression, adjusting for potential confounders and stratifying by sex and menopausal status.
Results: Participants with MetS (32 % of the study population) had higher concentrations for all urinary phthalate
metabolites. After full adjustment, higher DEHP metabolite concentrations were associated with an increased odds
of MetS in men, but not women (adj. POR for men Q4 versus Q1: 2.20; 95 % CI: 1.32, 3.68 and adj. POR for women Q4
versus Q1: 1.50; 95 % CI: 0.89, 2.52). When evaluating by menopausal status, pre-menopausal women with higher
concentrations of MBzP had close to a 4-fold increased odds of MetS compared to pre-menopausal women with the
lowest concentrations of MBzP (adj POR: Q4 versus Q1: 3.88; 95 % CI: 1.59, 9.49).
Conclusions: Higher concentrations of certain phthalate metabolites were associated with an increased odds of MetS.
Higher DEHP metabolite concentrations were associated with an increased odds of MetS for men. In women, the
strongest association was between higher concentrations of MBzP and MetS, but only among pre-menopausal women.
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Background
There is a growing body of predominantly cross-sectional
epidemiologic studies examining the association of phthal-
ate exposure with obesity [1–3], insulin resistance [4–6],
and blood pressure [7–9]. Little is known about the
association of phthalate exposure and metabolic syn-
drome (MetS). Comprised of central obesity, hypertri-
glyceridemia, hyperlipidemia, insulin resistance, and
hypertension [10, 11], MetS represents an integrated
measure of metabolic dysfunction. Captured by this
constellation of commonly measured clinical variables,
MetS is associated with an increased risk for cardiovascu-
lar disease and all-cause mortality by 50–200 % [12–15].
Lifestyle factors [16] and socioeconomic status [17, 18] are
strong predictors of MetS, and the prevalence of the
condition varies by sex and race/ethnicity [19, 20]. Based
on the National Health and Nutrition Examination Survey
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(NHANES), a nationally-representative sample from the
U.S. population between 2003 and 2013, the prevalence of
MetS is 33 % [21]. While obesity and insulin resistance are
components of MetS and are independently associated
with increased cardiovascular disease risk, MetS is a better
predictor of cardiovascular disease than its individual
components alone [22, 23]. As such evaluating the role
of phthalates on MetS may provide insight into whether
higher exposure to these chemicals might be associated
with MetS, and thereby increasing cardiovascular
disease risk.
As a class of endocrine disrupting chemicals, phtha-
lates are found in a variety of consumer products, in-
cluding food packaging, cosmetics, and vinyl flooring
[24]. Phthalate levels vary across the population, with
women and racial/ethnic minorities having higher con-
centrations of these chemicals compared to men and
whites [25, 26]. These differences in urinary phthalate
metabolite concentrations across the population may be
attributed to differences in behavioral patterns and life-
style factors that can alter phthalate exposure, such as
personal care product [27] and medication use [28], as
well as processed foods packaged in high molecular
weight phthalate-containing plastic [24]. For example, it
is hypothesized that women have higher concentrations
of certain urinary phthalate metabolites compared to
men due to their use of perfumes, nail polishes, and
other personal care products. A previous study showed
significant sex-phthalate interactions for ∑DEHP and
fasting blood glucose, as well as MBzP and fasting insu-
lin. Patterns of association were different, with stronger
associations seen in men for ∑DEHP and fasting glucose
compared to women. The opposite was true for the as-
sociation between MBzP and fasting insulin in women
compared to associations seen in men [4, 6]. Little is
known about the association between phthalates and
other components of MetS, namely hypertension, low
HDL and hypertriglyceridemia or with MetS as a
whole.
Phthalates are thought to contribute to obesity and in-
creased insulin resistance through a number of pathways.
For example, phthalates are known to bind to peroxisome
proliferator-activated receptor gamma (PPAR-γ), which
could upregulate adipocyte production and, in an environ-
ment with excess caloric intake, could contribute to insu-
lin resistance [29]. Phthalates are also known to modulate
hormones and inflammatory pathways [30], which could
subsequently lead to increased inflammatory profile and
insulin resistance [31]. Both adipogenic and inflammatory
pathways are known to be involved in MetS [32]. As such,
higher phthalate exposure could affect adipogenic or
inflammatory pathways to alter risk of MetS.
Given that the association between phthalates and
MetS remains unclear, we conducted an exploratory
analysis using data from the National Health and
Nutrition Examination Survey (NHANES) to evaluate
the association between eight phthalate metabolites and
MetS. We posited that associations between phthalate
metabolite concentrations and MetS would differ by sex
based on reported differences in the association of phthal-
ate metabolite concentrations with insulin resistance by
sex [4]. Given that menopause marks a time period of
increased incidence of MetS [33, 34], we also hypothesized
that the association between phthalate metabolites and
MetS might differ based on menopause status.
Methods
Study population
The National Health and Nutrition Examination Survey
(NHANES) is an ongoing survey conducted by the
National Center for Health Statistics. NHANES is a
nationally representative sample of the U.S. non-
institutionalized civilian population. A complex, multi-
stage probability sampling strategy is used, which
oversamples certain subgroups of the population, in-
cluding blacks, Mexican-Americans, and those of
lower socioeconomic status. Each year approximately
5000 individuals participate in NHANES, and the data
are reported in 2-year cycles available for public use.
Demographic, dietary, and behavioral information is
collected through in-home questionnaires, while trained
assistants collect anthropometric and biomarker data
using mobile exam units.
We identified 3431 participants aged 20–80 with single
measurements of urinary phthalate metabolites and data
on all five components for MetS. We excluded 396 with
missing covariate information, 131 pregnant or lactating
women and 185 participants with fasting time <8 hours.
These exclusions resulted in an analytic dataset of 2719
adults. Data were pooled from NHANES 2001–2010,
with analysis restricted to 2719 men and non-pregnant
and non-lactating women aged 20–80 years who had
fasted for ≥8 hours and had complete information on
phthalate exposure, outcome and covariates. As a part of
the NHANES protocol, informed consent was obtained
in writing from all study participants. This study was
approved by Brigham and Women’s Hospital’s Partners
Human Research Committee.
Measurement of phthalate metabolites
In a random one-third subsample of NHANES study
participants, phthalate metabolites were measured in a
spot urine sample. These samples are collected and
frozen at -20C and shipped to the National Center for
Environmental Health at the Centers for Disease Con-
trol for analysis of a variety of phthalate metabolites.
Phthalate metabolites are measured instead of their
parent compounds to lower the potential for exposure
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misclassification. A combination of solid phase extraction,
high pressure liquid chromatography, and tandem mass
spectrometry was used to measure phthalate metabolite
levels using methods described elsewhere [26].
The phthalate metabolites measured in NHANES study
participants varied by year. We selected a combination of
those that had been measured in previous studies showing
associations with metabolic derangements, as well as those
that were measured in all years with >60 % of sample con-
centrations above the limit of detection (LOD) [35]. Based
on these criteria, we evaluated mono-ethyl phthalate
(MEP), mono-n-butyl phthalate (MnBP), mono-isobutyl
phthalate (MiBP), mono-benzyl phthalate (MBzP), mono-
(3-carboxypropyl) phthalate (MCPP), and di(2-ethylhexyl)
phthalate (DEHP) metabolites (i.e. mono-(2-ethylhexyl)
phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl) phthal-
ate (MEHHP) and mono-(2-ethyl-5-oxohexyl) phthalate
(MEOHP)). Given that the DEHP metabolites were highly
correlated, we used the molar sum of these metabolites,
denoted by ΣDEHP. To allow potential non-linear asso-
ciations as previously found, we evaluated individual
phthalate metabolites and ΣDEHP using population-
specific quartiles. The lowest quartile was considered
the referent category. Those measured concentrations
below LOD were replaced with LOD divided by square
root of two, based on previous analyses [35].
Metabolic syndrome
We used the National Cholesterol Education Program’s
Adult Treatment Panel III report (NCEP/ATPIII) to define
MetS [36]. The NCEP/ATPIII classifies an individual as
having MetS, if at least 3 of the following 5 criteria are sat-
isfied: 1) waist circumference ≥ 102 cm in men or ≥ 88 cm
in women; 2) triglycerides ≥ 150 mg/dL; 3) high density
lipid (HDL) cholesterol < 40 mg/dL in men or <50 mg/dL
in women; 4) blood pressure ≥ 130/85 mmHg or treatment
for hypertension; 5) fasting blood glucose ≥ 100 mg/dL or
treatment for diabetes. Data on waist circumference and
blood pressure were collected from NHANES and details
are provided in the NHANES Anthropometry Procedures
Manual [37]. The average of all available measures after a
total of 4 attempted readings was used to indicate partici-
pants’ blood pressure levels. Fasting blood glucose, HDL
cholesterol, and triglyceride levels were assayed using
methods described in the NHANES Laboratory/Medical
Technologists Procedures Manual [38]. Information on
antihypertensive or anti-diabetic medication was self-
reported and collected from study questionnaires.
Covariates
Age, sex, race/ethnicity, physical activity, smoking status,
educational attainment, poverty status, total caloric intake,
and menopausal status in women were self-reported by
questionnaire. Race/ethnicity was classified as white
(referent), black, Mexican-American, or others. Age was
evaluated by 10-year age groups including 20- < 30, 30- <
40, 40- < 50 (referent), 50- < 60, 60- < 70, or 70- < 80 years.
The upper age limit was restricted to <80 years due to
NHANES classifying participants who were age >80 years
as 80 or 85 in some surveys to protect confidentiality.
Physical activity was assessed as self-reported participation
in vigorous, moderate or none (referent) recreational
physical exercise. Smoking status was categorized as
current, past, or never (referent) smoker and educational
attainment as high school graduate or less (reference),
some college, or college graduate or higher. Poverty status
was defined by income-to-poverty ratio <1 (below the
poverty level) versus ≥1 (reference) based on the federal
poverty threshold and household income information
[39]. Women were considered as postmenopausal if they
reported no regular menstrual periods due to menopause
or surgery. Further, total caloric intake was derived from a
one-time 24 h dietary recall in 2001–2002 and from the
average of two-day 24 h recalls in 2003–2010. Total
caloric intake was divided into quartiles, with the lowest
quartile considered as the referent category.
Statistical analysis
For all statistical analyses, sampling weights were in-
cluded in the dataset and applied in procedures available
in SAS 9.3 (Cary, NC) that appropriately accounted for
the stratification and complex sampling of NHANES.
These procedures included PROC SURVEYMEANS,
PROC SURVEYFREQ and PROC SURVEYLOGISTIC.
First, weighted means/standard errors and numbers/
percentages were calculated to describe demographic,
behavioral and metabolic differences between individ-
uals with and without MetS. Levels of log-transformed
concentrations of urinary phthalate metabolites were
evaluated by MetS status using weighted geometric
means and 95 % confidence intervals (CIs).
Next, logistic regression was used to estimate prevalence
odds ratios (PORs) and 95 % CIs as a cross-sectional
measure of associations between phthalate metabolites and
MetS. Model 1 adjusted for urinary creatinine, as duration
of urine collection may influence measured urinary con-
centrations of phthalate metabolites. Model 2 adjusted for
potential confounders, including age, sex, race/ethnicity,
total caloric intake, education, physical activity, smoking,
and poverty level. For these analyses, we used traditional
methods to adjust for creatinine [1, 4–6]. We also evalu-
ated associations between each urinary phthalate metabol-
ite and each component of MetS using the above-specified
models. To determine whether there was an association
between urinary phthalate metabolite concentrations and
the number of MetS components we used multivariable
ordinal logistic regression, adjusting for age, sex, race/eth-
nicity, total caloric intake, education, physical activity,
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smoking, and poverty level. Given that the pathophysiology
of MetS may differ by sex, similar statistical modeling was
performed separately in men and women.
Both age and menopausal status are important predictors
of MetS [33, 34]. In order to evaluate whether the associ-
ation between phthalates and MetS differed by age, we
evaluated this association stratified by <50 years vs.
≥50 years for men and women separately. To explore po-
tential differences by menopausal status, we evaluated the
association between phthalates and MetS in pre- versus
post-menopausal women.
Results
Of the 2719 adults in the study population, a total of
31.8 % of the participants (31.7 % in men and 31.9 % in
women) met NCEP/ATPIII criteria for MetS. Individ-
uals with MetS were older, more likely to be physically
inactive (p < 0.0001), less educated (p < 0.0001), and
ever smokers (p = 0.04) (Table 1). For men < 50 years
old, the prevalence of MetS was 23.6 %, compared with
44.0 % in men ≥ 50 years old. For women <50 years old,
the prevalence of MetS was 21.1 %, while 47.4 % of
women ≥ 50 years had MetS. For premenopausal
women in this study population, the prevalence of MetS
was 21.9 %, compared with 46.8 % in postmenopausal
women.
While materially urinary phthalate metabolite concen-
trations appeared somewhat higher in the MetS group
compared to the group without MetS, we found that
only concentrations of MCPP reached borderline signifi-
cance higher in the MetS men and women compared to
those without MetS (p = 0.05) (Table 2). In the overall
study population, there was a modest positive associ-
ation between MBzP and MetS. After full adjustment
there was a ~40 % increased odds of MetS among those
with higher MBzP levels compared to those with the
lowest levels (Q1) (adj. POR for Q2: 1.40 (95 % CI: 1.04,
1.89); adj. POR for Q3: 1.37 (95 % CI: 0.96, 1.96); and
adj. POR for Q4: 1.44 (95 % CI: 0.98, 2.12)) (Table 3).
This association was largely due to the positive associa-
tions observed in women (adj. POR for Q2: 1.55 (95 %
CI: 1.07, 2.26); adj. POR for Q3: 1.71 (95 % CI: 1.05,
2.80); and adj. POR for Q4: 1.69 (95 % CI: 0.97, 2.93)
compared with Q1. In contrast, no clear association was
observed between MBzP and MetS in men. On the other
hand, there was a significant positive association be-
tween ∑DEHP exposure and MetS for each of the higher
quartiles relative to the lowest quartile, with Q2 and Q3
being associated with a 64 % (adj. 95 % CI for Q2: 1.24,
2.17 and adj. 95 % CI for Q3: 1.22, 2.22) increased odds
of MetS. Those with the highest concentrations of
∑DEHP had a 94 % increased odds of MetS (adj. 95 %
CI for Q4: 1.35, 2.80). These associations were stronger
in men than for women. We did not observe significant
associations for MetS with other phthalate metabolites.
Also, given that DEHP and MBzP are moderately corre-
lated, when simultaneously adjusted for in our models,
similar associations between DEHP and MetS were
found, but associations between MBzP and MetS were
attenuated and became non-significant.
Overall the weighted proportions of study subjects
who met criteria for each individual component of
MetS were: 52.5 % for waist circumference; 30.0 % for
triglycerides; 28.9 % for HDL cholesterol; 28.6 % for
blood pressure; and 42.5 % for fasting blood glucose.
Only the associations between MBzP and ∑DEHP and
individual components of MetS are presented, as only
these phthalate metabolites were associated with MetS
(Table 4; See the Additional file 1: Table S1 for the
association between other urinary phthalate metabolites
and MetS components). In the overall population, we
found the highest quartile of MBzP had a significant
association with central obesity (defined as waist
circumference ≥ 102 cm men or ≥ 88 cm in women) and
hypertriglyceridemia, whereas higher ΣDEHP was asso-
ciated with central adiposity, hypertriglyceridemia, high
blood pressure, and hyperglycemia (Table 4). When
evaluating the association between urinary phthalate
metabolite concentrations and the number of metabolic
components, we found that the highest quartiles of MBzP,
MCPP, MiBP were associated with an increased odds of
having more metabolic abnormalities. Higher ∑DEHP
concentrations (those with concentrations in Q2, Q3, and
Q4) were associated with an increased odds of having
more metabolic abnormalities (Additional file 1: Table S2).
For women, higher urinary levels of MBzP were associ-
ated with an increased odds of central obesity (adj. POR
for Q4 versus Q1: 1.71; 95 % CI: 1.07, 2.73) and hypergly-
cemia (adj. POR for Q2: 1.52; 95 % CI: 1.05, 2.18 and adj.
POR for Q3: 2.06, 95 % CI: 1.31, 3.22 compared to Q1),
with a suggestive association with hypertriglyceridemia
(adj. POR for Q4 versus Q1: 1.75, 95 % CI: 0.98, 3.13).
Although an association between urinary MBzP and MetS
was not observed in men, exposure to the highest quartile
of MBzP was associated with a significantly increased odds
of central obesity (adj. POR: 1.71; 95 % CI: 1.06, 2.77), but
not with other components of MetS. In men, urinary
levels of ∑DEHP metabolites showed positive associations
with central obesity (adj. POR for Q4 versus Q1: 1.68;
95 % CI: 1.02, 2.79) and high blood pressure (adj. POR for
Q2: 1.59; 95 % CI: 1.05–2.40 and adj. POR for Q4 v. Q1:
1.85; 95 % CI: 1.12, 3.05). Suggestive findings were also
present for higher ∑DEHP metabolite levels and hypertry-
glyceridemia in men (adj. POR for Q4 v. Q1: 1.55; 95 %
CI: 0.97, 2.49). Weaker associations were found for
∑DEHP and these components in women, with only
hypertriglyceridemia reaching statistical significance (adj.
POR for Q2 v. Q1: 1.63; 95 % CI: 1.16, 2.28). When
James-Todd et al. Environmental Health  (2016) 15:52 Page 4 of 12
Table 1 Population characteristics by metabolic syndrome status in men and women
Men (n = 1388) Women (n = 1331)
MetS No MetS MetS No MetS
(n = 464) (n = 924) (n = 501) (n = 830)
Mean (SE)
Age (yrs)*, *** 51.7 (0.7) 42.7 (0.6) 52.6 (0.8) 42.8 (0.5)
BMI (kg/m2)*, *** 32.8 (0.3) 26.7 (0.2) 33.3 (0.4) 26.6 (0.2)
Waist circumference (cm)*, *** 114.0 (0.7) 95.8 (0.5) 107.2 (0.7) 89.3 (0.6)
Diastolic blood pressure (mmHg) 74 (0.7) 70 (0.5) 71 (0.7) 69 (0.4)
Systolic blood pressure (mmHg)*, *** 129 (0.9) 119 (0.6) 126 (0.9) 115 (0.7)
Triglycerides*, *** 250 (19.3) 124 (3.0) 188 (7.1) 98 (2.3)
HDL*, *** 41 (0.8) 51 (0.5) 49 (0.8) 63 (0.6)
Glucose*, *** 121 (2.0) 100 (0.7) 115 (1.8) 92 (0.4)
Urinary creatinine (mg/dL) 150 (4.0) 153 (3.3) 119 (2.9) 110 (3.5)
Total caloric intake (kcal)**** 2573 (57) 2616 (38) 1691 (35) 1820 (30)
N (%a)
Age*, ***
< 50 year 162 (44.7) 566 (67.3) 177 (39.1) 549 (68.3)
≥ 50 year 302 (55.3) 358 (32.7) 324 (60.9) 281 (31.7)
Menopausal status, ***
Premenopausal – – 181 (41.1) 544 (68.7)
Postmenopausal – – 320 (58.9) 286 (31.3)
Race/ethnicity*
Mexican-American 103 (8.2) 189 (9.8) 117 (8.3) 138 (6.0)
White 278 (81.5) 447 (69.8) 229 (69.3) 431 (72.6)
Black 56 (5.1) 191 (10.7) 103 (12.2) 154 (10.5)
Other 27 (5.2) 97 (9.7) 52 (10.2) 107 (10.9)
Physical activity*, ***
Vigorous 111 (25.0) 370 (43.5) 74 (15.7) 216 (29.1)
Moderate 138 (33.7) 194 (20.8) 147 (34.3) 237 (28.9)
No 215 (41.2) 360 (35.6) 280 (49.9) 377 (42.0)
Smoking**
Never 189 (45.3) 426 (46.1) 277 (52.3) 499 (56.4)
Current 102 (21.8) 261 (28.8) 106 (23.2) 167 (22.2)
Past 173 (32.9) 237 (25.2) 118 (24.5) 164 (21.4)
Education**, ***
High school or less 266 (48.4) 462 (40.9) 313 (52.3) 347 (33.7)
Some college 106 (27.5) 244 (28.5) 126 (29.3) 274 (34.8)
College graduates or higher 92 (24.1) 218 (30.6) 62 (18.4) 209 (31.5)
Poverty status****
Yes 64 (8.8) 147 (10.6) 139 (20.6) 146 (12.3)
No 400 (91.2) 777 (89.4) 362 (79.4) 684 (87.7)
*p < 0.0001 in men; **p < 0.05 in men; ***p < 0.0001 in women; ****p < 0.05 in women
aWeighted percentages after accounting for the sampling design
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evaluating the number of components of MetS, only
∑DEHP was associated with a greater number of meta-
bolic abnormalities in men, whereas among women,
higher concentrations of MBzP, MnBP, MiBP, and ∑DEHP
were associated with a greater number of MetS compo-
nents (see Additional file 1: Table S2 for details).
In men, higher concentrations of MBzP were associ-
ated with an elevated odds of MetS only for younger
men (adj. POR for Q4 of MBzP in men <50 years: 1.86;
95 % CI: 1.08, 2.55) (Table 5). A statistically significant
inverse association was found for higher concentrations
of MBzP relative to the lowest concentrations of this
phthalate metabolite for older men. While only older
men with concentrations in the low-moderate range for
∑DEHP showed a significant increased odds of MetS
(adj. POR for men ≥50 years for Q2 versus Q1: 2.57;
95 % CI: 1.02, 1.69), even older men in the higher con-
centrations of ∑DEHP (Q3 and Q4) showed a suggested
2-fold increased odds of MetS compared to men in the
lowest quartile of ∑DEHP. On the other hand, younger
men with the highest concentrations of ∑DEHP had the
strongest odds of MetS (adj. POR for men ≤50 years for
Q4 versus Q1: 2.47; 95 % CI: 1.50, 3.62) (Table 5).
In women, the association beween MBzP and MetS
was somewhat similar when evaluating women who
were <50 years versus ≥50 years of age (Table 5). On the
other hand, the association between ∑DEHP and MetS
was only seen among women <50 years. Specifically
higher levels of ∑DEHP were associated with over a 2-
fold increased odds of MetS compared to women who
had the lowest levels of ∑DEHP (adj. POR for Q4: 2.37;
95 % CI: 1.13, 4.97). No associations reached statistical
significance for women ≥50 years of age (n = 605).
For premenopausal women (n = 725), strong positive
associations were observed for MetS with both MBzP
and ∑DEHP. In fact, associations for both of these
phthalate metabolites were even stronger than that
seen in age- and sex-stratified analyses. Specifically,
pre-menopausal women with higher levels of MBzP
had an ~3 to 4-fold increased odds of MetS com-
pared to women with the lowest concentrations. Like-
wise, pre-menopausal women with higher concentrations
of ∑DEHP had a 2 to 3-fold increased odds of MetS rela-
tive to women with the lowest concentrations of ∑DEHP.
See Fig. 1. In contrast, no association was observed with
these or other phthalate metabolites in postmenopausal
women (n = 606) (Fig. 1).
Discussion
In this study, we found higher levels of MBzP and
∑DEHP to be associated with a increased odds of MetS
when compared to having the lowest concentrations in
the overall study population. These associations held
even after adjusting for a variety of sociodemographic
and lifestyle factors. When stratifying by sex, higher
levels of MBzP were associated with a greater odds of
MetS in women, while higher levels of ∑DEHP were
associated with an increased odds of MetS in men. The
associations between higher levels of certain phthalates
(i.e. MBzP and ∑DEHP) and MetS were stronger among
men ≥50 years and women < 50 years. Despite having
lower prevalence of MetS, the strongest association was
seen among pre-menopausal women, with over 3-fold
increased odds of MetS among those with the highest
levels of MBzP or ∑DEHP compared to those with the
lowest levels.
When assessing components of metabolic syndrome,
previous studies have found associations between
higher levels of certain phthalate metabolites and
diabetes [2, 30, 31], insulin resistance [4, 6], obesity
[1, 6, 40, 41], which are markers of cardiovascular
risk [42–44]. For example, a previous study showed
both MBzP and ∑DEHP to be associated with in-
creased insulin resistance and fasting glucose levels
among adult participants of NHANES 2001–2008 [4].
These associations differed in men and women, with a
suggestion of a stronger association between MBzP and
insulin resistance in women and a slightly stronger associ-
ation between ∑DEHP and fasting glucose in men [4]. The
present study also found similar associations of MBzP and
∑DEHP with hyperglycemia. The pattern of metabolites
with sex was in similar directions as previously reported
[4]. As such, this growing body of evidence suggests that
butylbenzyl phthalate, the parent compound of MBzP, and
DEHP may increase the odds of MetS through mecha-
nisms related to glucose dysregulation. Since the bulk of
the studies are cross-sectional, like the present study,
it is unclear whether higher butylbenzyl phthalate and
DEHP levels precede insulin resistance or hypergly-
cemia or a consequence of these conditions, possibly
attributed to differences in phthalate sources, such as
increased medication use. As such, other pathways
cannot be ruled out, nor can reverse causation. Future
Table 2 Urinary phthalate metabolites by metabolic syndrome
status
Metabolic syndrome No metabolic syndrome p-value
(n = 965) (n = 1754)
Geometric mean (95 % CI)
MEP 161.8 (140.7, 186.1) 142.9 (129.5, 157.7) 0.10
MBzP 10.4 (9.4, 11.7) 9.6 (8.7, 10.5) 0.26
MnBP 17.2 (15.7, 18.9) 16.2 (15.1, 17.5) 0.33
MCPP 2.8 (2.5, 3.1) 2.5 (2.3, 2.6) 0.05
MiBP 4.7 (4.2, 5.3) 4.4 (4.1, 4.7) 0.37
∑DEHP 0.13 (0.12, 0.15) 0.12 (0.10, 0.13) 0.06
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prospective studies will need to evaluate the exact mech-
anism by which these parent compounds might operate to
increase the risk of MetS.
A number of NHANES studies have documented an
association between higher phthalate metabolite concen-
trations and increased obesity and waist circumference
[6, 40, 41]. However, these findings differ by sex, with
higher concentrations of certain phthalate metabolites be-
ing associated with obesity and waist circumference only in
men [1]. The present study found similar associations in
both men and women for MBzP with a ~70 % increased
odds of central obesity based on MetS criteria for
both men and women. In fact, this component of
MetS was most strongly associated with higher
phthalate metabolite concentrations. The hypothesized
pathway by which phthalates are thought to alter adi-
posity is through their ability to bind to PPAR-γ and
upregulate target genes associated with adipogenesis
in an environment of excess caloric intake [29]. It is
also plausible that central obesity was strongly
Table 3 Prevalence odds ratios and 95 % confidence intervals for metabolic syndromes according to urinary phthalate metabolites
in men and women
Overall population Men Women
(n = 2719) (n = 1388) (n = 1331)
Model 1a Model 2b Model 1a Model 2c Model 1a Model 2c
MEP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.07 (0.82, 1.40) 1.16 (0.88, 1.54) 0.92 (0.63, 1.34) 0.98 (0.66, 1.45) 1.21 (0.84, 1.75) 1.46 (0.97, 2.19)
Q3 0.94 (0.69, 1.27) 0.98 (0.71, 1.37) 0.97 (0.62, 1.53) 0.97 (0.58, 1.61) 0.86 (0.59, 1.27) 1.02 (0.66, 1.56)
Q4 1.20 (0.91, 1.59) 1.18 (0.88, 1.59) 1.33 (0.90, 1.96) 1.35 (0.87, 2.11) 1.04 (0.71, 1.51) 1.11 (0.72, 1.72)
MBzP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.33 (1.00, 1.75) 1.40 (1.04, 1.89) 1.25 (0.83, 1.87) 1.19 (0.75, 1.87) 1.34 (0.96, 1.88) 1.55 (1.07, 2.26)
Q3 1.27 (0.92, 1.78) 1.37 (0.96, 1.96) 1.04 (0.68, 1.59) 1.01 (0.63, 1.63) 1.49 (0.95, 2.35) 1.71 (1.05, 2.80)
Q4 1.27 (0.86, 1.86) 1.44 (0.98, 2.12) 1.03 (0.62, 1.70) 1.08 (0.65, 1.79) 1.46 (0.90, 2.36) 1.69 (0.97, 2.93)
MnBP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.23 (0.92, 1.66) 1.21 (0.90, 1.63) 1.10 (0.73, 1.64) 1.06 (0.71, 1.58) 1.35 (0.95, 1.91) 1.31 (0.90, 1.89)
Q3 0.97 (0.71, 1.33) 0.94 (0.67, 1.33) 0.66 (0.41, 1.07) 0.57 (0.34, 0.96) 1.37 (0.99, 1.90) 1.45 (0.98, 2.16)
Q4 1.23 (0.88, 1.73) 1.22 (0.85, 1.75) 1.37 (0.87, 2.17) 1.43 (0.85, 2.40) 1.09 (0.69, 1.74) 1.03 (0.60, 1.77)
MCPP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.09 (0.82, 1.45) 1.05 (0.77, 1.44) 1.09 (0.74, 1.61) 0.96 (0.62, 1.49) 1.04 (0.71, 1.52) 1.05 (0.71, 1.57)
Q3 1.02 (0.72, 1.43) 0.94 (0.65, 1.34) 0.91 (0.60, 1.38) 0.75 (0.48, 1.18) 1.07 (0.68, 1.68) 0.97 (0.57, 1.66)
Q4 1.25 (0.91, 1.72) 1.12 (0.80, 1.56) 1.30 (0.85, 2.01) 0.99 (0.63, 1.58) 1.11 (0.72, 1.70) 1.08 (0.68, 1.71)
MiBP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.04 (0.78, 1.38) 1.07 (0.78, 1.47) 0.91 (0.64, 1.30) 0.94 (0.63, 1.38) 1.14 (0.73, 1.78) 1.13 (0.71, 1.81)
Q3 0.88 (0.64, 1.20) 0.88 (0.61, 1.27) 0.72 (0.46, 1.12) 0.72 (0.43, 1.19) 1.03 (0.66, 1.61) 1.04 (0.64, 1.70)
Q4 1.14 (0.86, 1.52) 1.28 (0.91, 1.80) 0.98 (0.69, 1.40) 1.05 (0.66, 1.65) 1.25 (0.74, 2.09) 1.40 (0.77, 2.55)
∑DEHP
Q1 Ref Ref Ref Ref Ref Ref
Q2 1.62 (1.25, 2.11) 1.64 (1.24, 2.17) 1.69 (1.23, 2.34) 1.60 (1.11, 2.31) 1.52 (1.07, 2.17) 1.58 (1.09, 2.29)
Q3 1.55 (1.16, 2.09) 1.64 (1.22, 2.22) 1.71 (1.17, 2.51) 1.69 (1.16, 2.46) 1.38 (0.86, 2.22) 1.43 (0.89, 2.29)
Q4 1.59 (1.12, 2.25) 1.94 (1.35, 2.80) 1.87 (1.19, 2.94) 2.20 (1.32, 3.68) 1.27 (0.78, 2.06) 1.50 (0.89, 2.52)
aAdjusted for urinary creatinine
bAdjusted for urinary creatinine, age, sex, race/ethnicity, total caloric intake, education, physical activity, smoking, and poverty
cAdjusted for the same variables in b except sex
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associated with MBzP and DEHP due to greater in-
take of high fat foods that may have been packaged
in phthalate-containing plastics, which would contrib-
ute to greater fat mass. Prospective studies, evaluating
potential mechanisms, are needed to disentangle these
associations.
Higher levels of ∑DEHP were associated with hyper-
glycemia and hypertriglyceridemia in the overall study
Table 4 Prevalence odds ratios and 95 % confidence intervals for individual components of metabolic syndrome according to
urinary phthalate metabolite levels
Individual metabolic abnormalities of metabolic syndrome
Central obesity Hypertriglyceridemia Low HDL cholesterol High blood pressure Hyperglycemia
Overall population
# with condition /total 1522/2719 849/2719 816/2719 871/2719 1289/2719
MBzPa
Q1 Ref Ref Ref Ref Ref
Q2 1.23 (0.93, 1.62) 1.20 (0.95, 1.51) 1.13 (0.81, 1.57) 0.87 (0.62, 1.21) 1.03 (0.75, 1.41)
Q3 1.34 (0.98, 1.85) 1.12 (0.84, 1.49) 1.12 (0.77, 1.63) 1.07 (0.68, 1.67) 1.36 (0.98, 1.88)
Q4 1.84 (1.31, 2.58) 1.50 (1.10, 2.05) 1.27 (0.86, 1.89) 1.18 (0.79, 1.75) 1.20 (0.80, 1.79)
∑DEHPa
Q1 Ref Ref Ref Ref Ref
Q2 1.40 (1.02, 1.92) 1.34 (1.01, 1.79) 1.35 (1.01, 1.80) 1.34 (0.96, 1.88) 1.20 (0.88, 1.64)
Q3 1.31 (0.95, 1.81) 1.33 (0.96, 1.82) 0.99 (0.74, 1.31) 1.28 (0.90, 1.81) 1.60 (1.13, 2.26)
Q4 1.66 (1.16, 2.36) 1.55 (1.12, 2.14) 1.05 (0.74, 1.49) 1.56 (1.14, 2.12) 1.66 (1.13, 2.44)
Men
# with condition/total men 639/1388 465/1388 357/1388 437/1388 758/1388
MBzPb
Q1 Ref Ref Ref Ref Ref
Q2 1.20 (0.75, 1.90) 1.21 (0.89, 1.66) 1.35 (0.88, 2.08) 0.84 (0.56, 1.27) 0.68 (0.40, 1.18)
Q3 1.11 (0.67, 1.83) 1.09 (0.75, 1.57) 1.14 (0.64, 2.04) 0.78 (0.47, 1.31) 0.96 (0.54, 1.38)
Q4 1.71 (1.06, 2.77) 1.28 (0.84, 1.95) 1.02 (0.62, 1.70) 0.89 (0.54, 1.48) 0.86 (0.48, 1.53)
∑DEHPb
Q1 Ref Ref Ref Ref Ref
Q2 1.42 (0.97, 2.07) 1.13 (0.75, 1.71) 1.17 (0.69, 1.98) 1.59 (1.05, 2.40) 1.15 (0.76, 1.74)
Q3 1.24 (0.79, 1.93) 1.34 (0.89, 2.02) 1.02 (0.62, 1.68) 1.38 (0.88, 2.16) 1.57 (0.95, 2.58)
Q4 1.68 (1.02, 2.79) 1.55 (0.97, 2.49) 0.98 (0.53, 1.80) 1.85 (1.12, 3.05) 1.67 (0.96, 2.93)
Women
# with condition /total women 883/1331 384/1331 459/1331 434/1331 531/1331
MBzPb
Q1 Ref Ref Ref Ref Ref
Q2 1.16 (0.79, 1.69) 1.17 (0.79, 1.73) 0.93 (0.60, 1.42) 0.82 (0.50, 1.36) 1.52 (1.05, 2.18)
Q3 1.46 (0.96, 2.22) 1.16 (0.71, 1.87) 1.06 (0.67, 1.67) 1.37 (0.74, 2.56) 2.06 (1.31, 3.22)
Q4 1.71 (1.07, 2.73) 1.75 (0.98, 3.13) 1.47 (0.84, 2.56) 1.40 (0.80, 2.47) 1.57 (0.90, 2.71)
∑DEHPb
Q1 Ref Ref Ref Ref Ref
Q2 1.24 (0.79, 1.93) 1.63 (1.16, 2.28) 1.38 (0.96, 1.99) 1.12 (0.67, 1.88) 1.18 (0.79, 1.77)
Q3 1.23 (0.80, 1.90) 1.23 (0.81, 1.89) 0.86 (0.57, 1.31) 1.19 (0.69, 2.07) 1.53 (0.94, 2.49)
Q4 1.38 (0.90, 2.12) 1.45 (0.88, 2.41) 1.04 (0.66, 1.63) 1.24 (0.82, 1.88) 1.56 (0.93, 2.59)
aAdjusted for urinary creatinine, age, sex, race/ethnicity, total caloric intake, education, physical activity, smoking, and poverty
bAdjusted for covariates in a except sex
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Fig. 1 a Prevalence odds ratios for the association between urinary MBzP concentrations and metabolic syndrome stratified by menopausal
status in women. b Prevalence odds ratios for the association between urinary ∑DEHP metabolites concentrations and metabolic syndrome
stratified by menopausal status in women. Prevalence odds ratios were adjusted for urinary creatinine, age, race/ethnicity, total caloric intake,
education, physical activity, smoking, and poverty
Table 5 Prevalence odds ratios and 95 % confidence intervals for metabolic syndromes stratified by age and sex
Men Women
<50 years ≥50 years <50 years ≥50 years
(n = 728) (n = 660) (n = 726) (n = 605)
MBzPa
Q1 Ref Ref Ref Ref
Q2 1.75 (1.02, 2.43) 0.94 (0.41, 0.73) 1.45 (0.74, 2.83) 1.71 (1.00, 2.92)
Q3 1.53 (0.86, 198) 0.79 (0.38, 0.75) 2.25 (1.13, 4.49) 1.23 (0.57, 2.63)
Q4 1.86 (1.08, 2.55) 0.67 (0.35, 0.74) 1.84 (0.80, 4.22) 1.82 (0.86, 3.85)
∑DEHPa
Q1 Ref Ref Ref Ref
Q2 1.08 (0.57, 1.20) 2.57 (1.02, 1.69) 2.38 (1.37, 4.14) 1.14 (0.63, 2.07)
Q3 1.60 (0.76, 1.71) 2.00 (0.79, 1.31) 1.85 (1.02, 3.37) 1.23 (0.61, 2.50)
Q4 2.47 (1.50, 3.62) 2.07 (0.96, 1.80) 2.37 (1.13, 4.97) 1.00 (0.49, 2.06)
a Prevalence odds ratios are adjusted for urinary creatinine, age, race/ethnicity, total caloric intake, education, physical activity, smoking, and poverty
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population. ∑DEHP was also associated with increased
central obesity and hypertension in men. A study of
elderly Swedish men and women found an association
between ∑DEHP and elevated LDL and carotid artery
plaques, a sign of cardiovascular disease [42]. Our findings
suggest that other CV risk factors, namely decreased HDL
cholesterol and hypertension, might be associated with
higher phthalate exposure. Future work will need to ex-
plore whether phthalates might be associated with cardio-
vascular disease, a leading cause of mortality in the U.S.
In the present study, analyses were stratified by several
factors, including sex, age, and menopausal status, as
phthalate metabolite concentrations and the prevalence of
MetS may differ by these [4, 25, 33, 34]. Associations were
stronger among young women and older men. It is pos-
sible that these differences are due to differing hormonal
states and possibly by the effects of aging. In women, we
saw that independent of age, there was a different associ-
ation between certain phthalate metabolites and MetS
based on menopausal status. However, the reasons for sex
and age differences are unclear and require further investi-
gation. Based on data from NHANES, U.S. women have
higher concentrations of MEP, MBzP, MnBP, MiBP, MCPP,
and ∑DEHP compared to U.S. men [25]. From the same
study, urinary phthalate metabolite concentrations were
lower in those ≥40 years of age than in those <20 years of
age [25]. Based on another previous study using NHANES,
higher concentrations of DEHP metabolites were associ-
ated with earlier age at menopause among women who
participated in NHANES [45]. While it is possible that
phthalates may modulate estrogen levels [46], phthalates
could also affect age at menopause, with implications for
conditions that are more prevalent in post-menopausal
women. Future studies will need to elucidate these associa-
tions to better understand these potential differences by
sex, age, and menopausal status.
Butyl benzyl phthalate, the parent compound of MBzP
is commonly found in personal care products, food
packaging, and industrial solvents [24]. While ∑DEHP
was once thought to be of greatest concern due to hav-
ing many common sources of exposure, such as polyvi-
nyl plastics containing this phthalate parent compound,
more recently other metabolites, such as MBzP have
been seen as an important phthalate metabolite [24].
Although there have been some decreases in exposure
to certain phthalates over time [47], these chemicals are
still used in consumer products and are being replaced
by similar chemicals without known health effects. In
fact, a recent study found similar associations with a
replacement compound, diisononyl phthalate [7].
This study has several limitations. First, due to the
cross-sectional study design, we are unable to establish
temporality and could not rule out the possibility of
reverse causation. For example, higher phthalate
metabolite concentrations could be a consequence of
having MetS rather than higher phthalate metabolite con-
centrations influencing MetS. Second, this study used a
one-time measurement of phthalate metabolite levels in
the study population. A single fasting measure may not ad-
equately capture overall exposure to urinary phthalate me-
tabolites, leading to non-differential misclassification. As
such, we may underestimate the associations between urin-
ary phthalate metabolites and metabolic syndrome in this
study population. Phthalates are non-persistent chemicals
and are rapidly excreted within 24–48 h [24]. These chemi-
cals are known to vary within a person over time and have
a moderate reliability over time with intraclass correlations
for creatinine-adjusted urinary phthalate metabolite con-
centrations ranging from 0.39 to 0.55 based on women
participating in the Nurses’ Health Study [48]. Another
study found very low reproducibility with intraclass
correlations ranging from 0.03 to 0.20; however, these
study participants were all living in Shanghai, which may
have different patterns of exposure compared to individ-
uals living in the U.S. [49]. Given that MetS may take years
or decades to develop, the short half-life of these chemicals
may only be relevant, if exposure to higher concentrations
of phthalates is on average consistent across time. Future
studies will need to evaluate repeated measures of these
chemicals across multiple time points to determine their
association with MetS and its components.
Third, due to the cross-sectional nature of the study,
we were unable to determine whether higher exposure
to these chemicals was attributed to exposures that were
the effect of MetS, such as increased medication and
personal care product use, as well as intake of food
products packaged in DEHP-containing plastics or foods
that are high in fat, such as protein, dairy, and cooking
oil [24]. However, adjusting for the sources of exposure
would not yield an accurate measure of association
Fourth, the fact that study participants fasted could
underestimate the associations for ∑DEHP and MetS, as
concentrations may be lower due to not having taken
foods that are a primary source of exposure to this par-
ent compound. Finally, the lack of dose–response associ-
ations could either signal threshold effects, the
possibility of negative feedback loops, or residual
confounding.
Despite these limitations, the present study has several
strengths. First, this study was able to evaluate 5 different
phthalate metabolites, as well as a summary measure of
the DEHP metabolites and their associations with MetS
among a substantial study population of U.S. adults.
Second, data were utilized from a representative sample of
the U.S. population that was comprised of both men and
women that was racially/ethnically diverse. Third, analyses
were stratified by sex and age, as well as menopausal
status, to determine whether associations differed by
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subgroups based on a priori hypotheses. Fourth, the data-
set utilized the widely accepted criteria for MetS based on
the NCEP/ATPIII classification. These findings provide in-
sights into a prevalent chemical exposure on MetS as a
cardiovascular risk marker.
Conclusion
In conclusion, in this cross-sectional study, we found
MBzP and ∑DEHP to be associated with an increased odds
of MetS. The associations suggestively differed between
men and women depending on the phthalate metabolite
studied and by each component of MetS. Associations
appeared to be the strongest for premenopausal women
with higher levels of MBzP and ∑DEHP and MetS. These
findings suggest further evaluating the role of phthalate
metabolite concentrations prospectively to determine
whether these chemicals can alter the risk of MetS among
individuals without the condition. Furthermore, additional
work is needed to understand the roles of sex, age, and
menopausal status on the associations between phthalate
metabolite levels and MetS. If replicated, these findings
suggest that phthalates could be a potentially modifiable
risk factor of MetS.
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